Cerebrolysin vs Omberacetam (Noopept)
Cerebrolysin has a broader RCT literature in neurologic disease but mixed indication-specific results; Noopept human evidence is smaller and more often open/comparative.
| Attribute | Cerebrolysin | Omberacetam (Noopept) |
|---|---|---|
| Human evidence | Multiple randomized trials and meta-analyses exist, but results differ by indication. Alzheimer trials show some short-term cognitive/global signals, whereas the 2023 Cochrane stroke review found no mortality benefit and a potential increase in non-fatal serious adverse events. | Human evidence consists mainly of older regional open/comparative studies in patients with vascular or traumatic cognitive impairment; no modern placebo-controlled healthy-adult cognitive-enhancement programme was identified. |
| Research focus | Alzheimer disease, acute ischaemic stroke, traumatic brain injury, cognitive recovery | Post-stroke cognitive impairment, mild cognitive impairment, neuroprotection; commonly discussed as a nootropic |
| Regulatory status | Regulatory availability varies by country; it is not an FDA-approved cognitive enhancer. Jurisdiction-specific product status must be checked separately. | FDA substance records identify omberacetam/Noopept but explicitly note that UNII listing does not imply regulatory review or approval. Regulatory status varies internationally. |
| Route / formulation | Evidence applies to a specific biologic mixture formulation, commonly administered intravenously in trials; generic 'peptide blends' are not equivalent. | Most clinical literature concerns oral use in neurologic patients; it should not be extrapolated to other formulations or healthy-user 'nootropic' protocols. |
Why these are compared
These compounds appear in the brain & cognitive performance evidence landscape, but they are not interchangeable. Cerebrolysin is porcine brain-derived mixture of low-molecular-weight peptides and amino acids studied in alzheimer disease, acute ischaemic stroke, traumatic brain injury, cognitive recovery; Omberacetam (Noopept) is synthetic peptidomimetic / dipeptide-derived small molecule studied in post-stroke cognitive impairment, mild cognitive impairment, neuroprotection; commonly discussed as a nootropic. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Cerebrolysin: Human clinical evidence — indication-dependent / regionally marketed.
Omberacetam (Noopept): Limited older human clinical evidence; healthy cognitive enhancement unestablished.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No direct head-to-head trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.